IP Library › Patent Application 18069489
Patent Application
App. No. 18/069,489

APPROACH FOR TREATMENT OF CANCER VIA IMMUNOMODULATION BY USING TALABOSTAT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/069,489
Abstract

The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.

Claims (1)

1 . A pharmaceutical composition comprising an effective amount of Talabostat and an effective amount of Nivolumab.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2023
From: JAZZ PHARMACEUTICALS, INC.
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 062735/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2023
From: MCMAHON, SARAH; OKI, YASUHIRO
To: JAZZ PHARMACEUTICALS, INC.
Reel/Frame 062735/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2023
From: BIOXCEL CORPORATION
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 062643/0029 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2023
From: BIOXCEL THERAPEUTICS, INC.
To: ONKOSXCEL THERAPEUTICS, LLC
Reel/Frame 062643/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2023
From: RASTELLI, LUCA; SAPRA, APARNA KATOCH; MEHTA, VIMAL
To: BIOXCEL CORPORATION
Reel/Frame 062692/0704 →